Unknown

Dataset Information

0

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

ABSTRACT: Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) may soon replace routine electrophoretic methods for monitoring monoclonal proteins in patients with multiple myeloma. To further evaluate the clinical utility of this assay, we compared the performance of MALDI-TOF-MS head-to-head with an established bone marrow-based measurable residual disease assay by flow cytometry (Flow-BM-MRD), using Memorial Sloan Kettering Cancer Center's 10-color, single-tube method. Our results suggest that MALDI-TOF-MS adds value to bone marrow-based MRD testing and may be most useful for early detection of relapse in peripheral blood compared to current electrophoretic methods.

SUBMITTER: Eveillard M 

PROVIDER: S-EPMC7275888 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

Eveillard Marion M   Rustad Even E   Roshal Mikhail M   Zhang Yanming Y   Ciardiello Amanda A   Korde Neha N   Hultcrantz Malin M   Lu Sydney S   Shah Urvi U   Hassoun Hani H   Smith Eric E   Lesokhin Alexander A   Mailankody Sham S   Landgren Ola O   Thoren Katie K  

British journal of haematology 20200205 5

Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) may soon replace routine electrophoretic methods for monitoring monoclonal proteins in patients with multiple myeloma. To further evaluate the clinical utility of this assay, we compared the performance of MALDI-TOF-MS head-to-head with an established bone marrow-based measurable residual disease assay by flow cytometry (Flow-BM-MRD), using Memorial Sloan Kettering Cancer Center's 10-color, single-tube me  ...[more]

Similar Datasets

Unknown Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
| S-EPMC8405199 | biostudies-literature
Unknown Bacteria spatial tracking in Urban Park soils with MALDI-TOF Mass Spectrometry and Specific PCR.
| S-EPMC9840317 | biostudies-literature
Unknown Rapid Determination of Procyanidins Using MALDI-ToF/ToF Mass Spectrometry.
| S-EPMC6296472 | biostudies-literature
Unknown Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.
| S-EPMC10105368 | biostudies-literature
Unknown Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
| S-EPMC7994191 | biostudies-literature
Unknown Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry.
| S-EPMC3922009 | biostudies-literature
Unknown Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
| S-EPMC8525140 | biostudies-literature
Unknown Measurable residual disease in multiple myeloma: ready for clinical practice?
| S-EPMC7310444 | biostudies-literature
Unknown Fragmentation characteristics of collision-induced dissociation in MALDI TOF/TOF mass spectrometry.
| S-EPMC2553356 | biostudies-literature
Unknown Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
| S-EPMC7873068 | biostudies-literature